Skip to main content
Equibles
PMVP logo

PMVP · PMV Pharmaceuticals, Inc.

Track PMVP — free

Use PMVP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PMVP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.22 -0.02 (-1.61%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has determined that the Company's current available cash, cash equivalents and marketable securities may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$65.49M
Shares
53.46M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.22 Open$1.25 Day$1.22–1.25 52W close$1.02–1.80 Avg vol 30d269K Short int2.2M · 4.2% float · 5.9d Short vol65% Last earningsMay 27, 2025 DataSep 2020–Aug 2026 Filing10-Q · Aug 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −2%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 26%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +10%
trailing
6-month return −25%
trailing
YTD return −2%
this year
Relative strength −39%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.20% of float · ▼ -5.6% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
64 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Poor
EPS growth −30%
Y/Y
Free cash flow $-73.6M
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −42%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 6 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−2% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.20% of float · ▼ -5.6% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
64 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 26% Range high $2
vs 200-day avg -4% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $79.4M second quarter ended June 30, 2026 —
Net cash used in operations $34.3M six months ended June 30, 2026 —
Median duration of response 8.2 Q1 FY2026 —
Median time to response 1.3 Q1 FY2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PMVP
PMV Pharmaceuticals, Inc.
this stock
$65.49M -2.4% — — 4.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
64
% held
64.5%
Net QoQ
-2.5M sh
Top holder
BML Capital Management, L…
Held Float
View
Held by Funds
Fund positions
26
View
Short & Settlement
Short Interest Falling
Shares short
2.2M
Days to cover
5.9d
Change
-133.9K sh
View
Short Volume
Short vol %
65%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$1
As of
Jun 26, 2026
View
Off-Exchange
Off-exchange %
41.6%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-77.7M
EPS diluted
$-1.48
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
8
View
Proposed Sales
Value
$1.5M
Shares
1.0M
Filed
Oct 23, 2025
View
Earnings & Events
Earnings Calls
Last call
May 27, 2025
View
Investor Relations
Latest news
PMV Pharmaceuticals Reports Secon…
Published
Aug 14, 2026
View

Performance

5D 20D 120D MTD YTD
PMVP -8.3% +9.9% -25.2% +9.9% -2.4%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -8.7% +6.9% -38.6% +6.9% -15.2%
Key facts CIK 1699382 CUSIP 69353Y103 13F (30d) 63 filings 63 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)